The in vitro activities of DX-619, des-fluoro(6) quinolone, against 1,208 clinical isolates were examined. DX-619 was particularly potent against staphylococci, including ciprofloxacin-and methicillin-resistant strains; the MIC at which 90% of the strains tested were inhibited was 0.5 g/ml. In addition, DX-619 was also active against gram-negative bacteria.
minocycline, quinupristin-dalfopristin, teicoplanin, and vancomycin were purchased from the manufacturers or Sigma Aldrich Japan (Tokyo, Japan). Each drug was used as an anhydrous free base.
Bacterial strains were collected by the Levofloxacin Surveillance Group from patients in Japan in 2000 (20) , with the exception of the strains mentioned below. Streptococcus agalactiae, Neisseria gonorrhoeae, Stenotrophomonas maltophilia, and anaerobic bacteria isolated in Japan were obtained from BML, Inc. (Saitama, Japan). Five ciprofloxacin-resistant strains of Streptococcus pneumoniae were isolated in Asia and Europe in 1997 and 1998 (16) , and nine such strains were collected by the Levofloxacin Surveillance Group in Japan in 2002 (21) . VRE were obtained from Creighton University (Omaha, Nebr.) and from Kyoto Pharmaceutical University and Gunma University in Japan.
MICs were determined according to the standard agar dilution method recommended by NCCLS (11) for bacterial species other than Haemophilus influenzae and anaerobes, for which the agar dilution method recommended by the Japanese Society of Chemotherapy was used (7) . Mueller-Hinton agar (Becton Dickinson, Sparks, Md.) supplemented with 5% sheep blood (Kohjin Bio Co., Ltd., Saitama, Japan) was used for streptococci and Moraxella catarrhalis, and GC agar (Becton Dickinson) was used for N. gonorrhoeae. Mueller-Hinton agar supplemented with 5% Fildes enrichment (Becton Dickinson) was used for H. influenzae, and modified Gifu anaerobe medium agar (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) was used for anaerobic bacteria. Drug-containing agar plates were incubated with one loopful of inoculum, corresponding to about 10 4 CFU (about 10 5 CFU for S. pneumoniae) per spot, and were incubated at 35°C for 20 h (48 h for Peptostreptococcus spp. and Clostridium difficile). N. gonorrhoeae was incubated under 5% CO 2 , and anaerobic bacteria were incubated (12) . The quality control strains recommended by NCCLS were included as internal controls throughout the study. Table 1 shows the antibacterial activity of DX-619 against gram-positive bacteria in comparison with those of reference compounds. The MIC 90 s (MICs at which 90% of isolates are inhibited) of DX-619 against methicillin-susceptible Staphylococcus aureus and methicillin-susceptible coagulase-negative staphylococci were both 0.015 g/ml. MIC 90 s of DX-619 against ciprofloxacin-susceptible MRSA, ciprofloxacin-resistant MRSA, and MRCNS were 0.008, 0.5, and 0.12 g/ml, respectively. Against staphylococci, DX-619 showed the most potent activity among the compounds tested, including antigram-positive agents. DX-619 was especially potent against ciprofloxacin-resistant MRSA, inhibiting the growth of all strains at 1 g/ml, a MIC 2-fold lower than those of vancomycin and linezolid, 4-fold lower than those of teicoplanin and quinupristin-dalfopristin, and at least 16-fold lower than those of the other compounds tested. MIC 90 s of DX-619 against penicillin-susceptible S. pneumoniae, penicillin-resistant S. pneumoniae, Streptococcus pyogenes, and S. agalactiae were 0.015, 0.03, 0.015, and 0.12 g/ml, respectively. Against 19 strains of ciprofloxacin-resistant S. pneumoniae, MICs of DX-619 ranged from 0.015 to 0.12 g/ml, and the activity was also the highest among the compounds tested. MIC 90 s of DX-619 against vancomycin-susceptible and -resistant Enterococcus faecalis were 0.25 and 0.5 g/ml, respectively, and MIC 90 s against vancomycin-susceptible and -resistant Enterococcus faecium and vancomycin-resistant Enterococcus gallinarum were all 2 g/ml. The activity against these VRE was also the highest among the reference compounds. DX-619 inhibited 90% of isolates of Peptostreptococcus spp. and C. difficile at 0.5 and 2 g/ml, respectively. The antibacterial activity of DX-619 against gram-negative strains is shown in Table 2 . DX-619 showed good antibacterial activity against H. influenzae, including ampicillin-resistant strains, and M. catarrhalis, against which the highest MIC was 0.06 g/ml. DX-619 inhibited 90% of isolates of Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp., Salmonella spp., Proteus mirabilis, indole-positive Proteus, and Serratia marcescens at 1, 0.12, 0.5, 1, 0.06, 2, 0.5, and 2 g/ml, respectively, and these activities were comparable to those of levofloxacin. DX-619 also showed activity comparable to that of levofloxacin against ciprofloxacin-susceptible P. aeruginosa, with a MIC 90 of 1 g/ml. The MIC 90 of DX-619 against ciprofloxacin-resistant P. aeruginosa was 64 g/ml. Against Acinetobacter spp. and N. gonorrhoeae including ciprofloxacin-resistant strains, DX-619 showed good antibacterial activity; the highest MIC against these species was 2 g/ml. The MIC 90 of DX-619 was 0.5 g/ml against Bacteroides fragilis. The MICs of the compounds tested against the reference strains for quality control were reproducible throughout the study.
This study showed that DX-619, a recently discovered desfluoro(6) quinolone, possesses the most potent antibacterial activity among the compounds tested against gram-positive bacteria, including ciprofloxacin-resistant MRSA, MRCNS, VRE, and ciprofloxacin-resistant S. pneumoniae. The most common resistant pathogen in hospitals is MRSA, which accounts for outbreaks and is increasing in frequency in many facilities (5) . The MIC 90 of DX-619 for ciprofloxacin-resistant MRSA was 0.5 g/ml, which was lower than those of linezolid and vancomycin. This finding may be attributable to the high inhibitory activity of DX-619 against altered target enzymes of MRSA (M. Tanaka et al., 43rd ICAAC, abstr. F-1060). The relative potency of DX-619 will be better understood when the human pharmacokinetics are available. Further studies of DX-619 are warranted based on the available data.
